Gold nanoparticles offered to ALS patients in expanded access program

NCT ID NCT05281484

NO_LONGER_AVAILABLE Disease control Sponsor: Clene Nanomedicine Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This program provides CNM-Au8, a suspension of gold nanocrystals, to up to 300 people with ALS. The main goal is to give access to the drug and monitor safety, not to test if it works. Participants must have a confirmed ALS diagnosis and be at least 18 years old.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CNM-Au8 (nanocrystalline gold suspension)
What this could lead to: If successful, this could provide a treatment option for ALS patients, potentially slowing disease progression.
What could go wrong: This is an expanded access program, not a formal trial, so it won't prove effectiveness. Safety is the main focus, and benefits are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

amyotrophic lateral sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AMYOTROPHIC LATERAL SCLEROSIS

Contacts and locations

Locations

Barrow Neurological Institute

Phoenix, Arizona, 85013, United States
DUKE University Medical Center (Enrollment is full, not recruiting)

Durham, North Carolina, 27705, United States
Henry Ford Health Systems (Enrollment is full, not recruiting)

Detroit, Michigan, 48322, United States
Hospital for Special Care (Enrollment is full, not recruiting)

New Britain, Connecticut, 06053, United States
Jefferson Hospital (Enrollment is full, not recruiting)

Philadelphia, Pennsylvania, 19107, United States
Massachusetts General Hospital (Enrollment is full, not recruiting)

Boston, Massachusetts, 02114, United States
Northwestern (Enrollment is full, not recruiting)

Chicago, Illinois, 60611, United States
Nova Southeastern University

Davie, Florida, 33314, United States
Penn State Health (Enrollment is full, not recruiting)

Hershey, Pennsylvania, 17033, United States
Providence Health (Enrollment is full, not recruiting)

Portland, Oregon, 97225, United States
Sutter Health (Enrollment is full, not recruiting)

San Francisco, California, 94107, United States
Texas Neurology

Dallas, Texas, 75206, United States
UC Irvine

Orange, California, 92868, United States
University of Kansas (Enrollment is full, not recruiting)

Fairway, Kansas, 66205, United States
University of Nebraska Medical Center (Enrollment is full, not recruiting)

Omaha, Nebraska, 68198, United States
University of Washington

Seattle, Washington, 98195, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.